Revvity cuts 2024 revenue forecast amid biotech spending slowdown
Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.
Revvity to Report Q3 Earnings: What's in Store for the Stock?
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity Shares Decline Despite Launch of Transcribe AI Solution
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
Reasons to Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
MD or RVTY: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
MD or RVTY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Diagnostic Products Demand Boosts Profit and Sales at Revvity
Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidance on higher demand for its diagnostic products.
Revvity, Inc. (RVTY) Q2 2024 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan Tycho Peterson - Jefferies Operator Hello, and welcome to the Q2 2024 Revvity Earnings Conference Call. My name is Elliott, and I'll be coordinating your call today.
